Skip to Content

Posts tagged with "Drug Industry History"

  • "Me Too" Drugs

    The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in drug projects over the last 20 years (both the successful ones and the unsuccessful ones). The authors (from Vertex) used the Cortellis commercial database (with a good deal of filtering an… Read More
  • Drug Assays

    Whole Classes of Things

    We all know about target-based drug discovery. Enough biology has been learned that we think that Protein X is operating at a crucial stage in the development of Disease A, so we’re going to try to find an inhibitor/agonist/antagonist, a ligand/allosteric modulator/binder/potentiator, or something to somehow affect its actions. We’ve se… Read More
  • Clinical Trials

    Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the “up” moments, for sure. The company (in collaboration with Sanofi) has just announced positive Phase 3 data on their therapy for hereditary ATTR amyloidosis – Read More
  • Drug Industry History

    Where MRSA Came From

    OK, everyone recognizes the problem that we face with drug-resistant bacteria. MRSA (methicillin-resistant Staphylococcus aureus) is the most well-known variety, and it’s bad news. Penicillin was introduced in the 1940s, and methicillin was brought to market in 1959, largely because so many infections were becoming resistant to penicillin by… Read More
  • Drug Development

    How Long, Oh Lord, How Long?

    Here we have the prototypical slow summer day. So I’m going to use this one to throw a question out to the readership: those of you in preclinical drug discovery, what’s the longest you’ve personally worked on a project that eventually managed to deliver a clinical candidate? On the not-so-inspiring side, what’s the longest… Read More
  • Business and Markets

    GSK Rearranges, Once More

    There have been a lot of announcements in the biopharma field this week, and I’m just now getting around to GlaxoSmithKline’s from a couple of days ago. The company announced that they’re dropping 30 R&D programs and refocusing the ones that are left. Cancer and immunology are now back in favor, and rare disease programs… Read More
  • Cancer

    The Keytruda Story

    This is a good history of Keytruda, the Merck immuno-oncology blockbuster, from David Shaywitz. Most big drugs have a tangled history, and this one is certainly not going to break tradition. As witness: It was discovered accidentally, by biotech scientists looking for drugs that would tamp down the immune response in patients with autoimmune diseas… Read More
  • Biological News

    Hemophilia: A Proving Ground For Genetic Disease

    There’s very good news for Alnylam (and their partner Sanofi) this morning. They’ve been working on an RNAi approach to hemophilia (fitusiran), targeting expression of antithrombin, a protein which as the name implies which keeps blood from clotting by several different mechanisms. The clinical data that have just come out look very en… Read More
  • Business and Markets

    Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percentage of the projects should be new ones, and how many should be some form of follow-up? I say that there may not be a general answer because every place I’ve worked has… Read More
  • Business and Markets

    China’s Biopharma Rise

    This story by Damien Garde at Stat is well worth a look. It goes into a question that people in biopharma have been asking themselves for some years now: when does China move from a contractor to a competitor? This was brought home by the recent results at the ASCO meeting from Nanjing Legend, who… Read More
...234...